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Dr William Bogey (Greenville, NC). I would like to thank the
association for the opportunity to discuss this paper, and Dr. Pearce
and colleagues for providing me with a copy of the manuscript in acurrent president, is well known for their expertise in the open
operative management of renovascular disease. This paper discusses
their experience with endovascular treatment of this disease process,
and, as we’ve come to expect, they have done an excellent job.
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September 2008588 Corriere et alEarly results were examined, and at a median of approximately
9weeks post procedure, statistically significant decreases in mean
systolic and diastolic BP as well as number of antihypertensive
meds were observed. When looked at categorically, however, only
approximately 22% had their hypertension helped, and 28% had
their renal insufficiency improved, while about 7% experienced a
worsening of renal function.
In reviewing this manuscript, a number of questions entered
my mind. I must confess, however, that many of these questions
were answered in the discussion section of the manuscript, and I
had to strike them from my list. Of course, I do still have a couple
of questions remaining. First, you note that previous experience
led you to the technical approach used. Can you enlighten us as to
the specifics of this technique? In particular, you feel that distal
protection is of value. My bias has been that the majority of
embolic debris that may damage the kidney is generated during the
process of gaining access to the artery, and thus by the time the
distal protection device has been deployed, the cat may well be out
of the bag. Do you feel differently, or does your technique allow
you to minimize this risk?
Secondly, you note that the results obtained here are better
when “complete” treatment is done, yet you also state that it is not
uncommon to perform only partial treatment in your current
algorithm. Will the results of this study cause you to alter this
algorithm?
Finally, you note that the magnitude of improvement follow-
ing percutaneous treatment is significantly less than that seen after
open therapy and you suggest that the trade-off in results versus
morbidity may be acceptable. My question is why is the magnitude
of improvement so much less? My admittedly naïve understanding
leads me to think that an open artery by any technique should give
a similar result, so why are the outcomes so dramatically different.
This study is only looking at short-term response, not the long-
term outcome that one might expect to favor surgery, eliminating
the bias improved long term durability might provide. It doesn’t
appear to me that it can all be explained by the lack of complete
treatment in the 21% in this study. Do you have any insight as to
why this may be? Is it continued microembolism from the diseased
aorta or renal artery, or perhaps the damage caused by the debris
that gets generated before the protection device is in place? Is it
that you are actually getting a less “complete” repair than your
ultrasound data would suggest, or is it perhaps some other factor?
Has the decreased morbidity caused you to expand your indica-
tions to include patients who would not have met your open repair
indications? I would appreciate your thoughts on this, as themagnitude of the difference in response between open and endo-
vascular repair shown by your group is indeed sobering.
Once again, I think the association for this opportunity, and I
look forward to hearing your response.
Dr. Pearce. Your first question involves the technical aspects
of distal embolic protection and why we continue to employ distal
protection. A paper presented last year at this meeting by Dr.
Corriere, categorized our embolic data from this procedure and
very nicely demonstrated the large amount of debris liberated by
angioplasty and stenting. Indeed you are correct that the previous
ex-vivo data demonstrated that just passing the guide wire results
in a large amount of embolic debris. We feel there is additional
benefit for catching the embolic debris that occurs with the angio-
plasty procedure itself.
Why are we still doing staged repair vs. complete intervention?
Our treatment algorithm involves treating patients with bilateral
disease in a unilateral fashion and then reassessing their response
including blood pressure control, hypertension medications uti-
lized, as well as renal function response. If the patient has an
adequate renal function and blood pressure response, we will
continue to maximize the medical management of atherosclerotic
risk factors and defer further intervention for observation. You
referred to the additional data and figure included in the paper. I
did not present that here because it confuses the issue a little. The
unadjusted results of the group as a whole suggested that patients
with bilateral disease undergoing bilateral repair favored better
than those undergoing unilateral repair. Unilateral repair of bilat-
eral disease was not common in this patient group and the results in
the figure are not adjusted for preoperative values. Moreover,
when a multivariable regression analysis was performed we did not
observe the same renal function benefits with complete vs. incom-
plete repair.
Your final question inquires as to why the results here less
favorable than those observed in our open repair experience? I
think that there are a number of factors that can play into that
observation, but this paper was not designed to provide a direct
comparison between open and percutaneous results. However,
when we compared the demographics of the patients in the percu-
taneous group to the demographics of the open group, we had
more diabetics in the percutaneous group. Additionally, the per-
cutaneous patients tended to be older by at least five years with less
renal insufficiency compared to the open group. Finally, I think
you have correctly mentioned additional factors that could also be
in play for the discrepancies in renal function response observed
which include the recognized residual disease and the effects of
embolization.
